ImmunoGen Message Board - Msg: 32401899

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Mohilner who wrote (5623)	11/3/2019 5:46:11 PM
From: Area51	Read Replies (1) of 5665

Nice to see some positive action Friday. Of course one day does not necessarily make a trend. It was a fun stock to own from early 2017 to Q2 2013 when it ran from 2 to 13, but since then has mostly just been a house of pain. To me its not an easy trade here, as downside catalysts (e.g. - run out of money late next year and dilute) seem perhaps more likely then upside catalysts (a significant partnership, or SGEN buys them out at a premium). This is a fair summary of IMGN's status? After the stock tanked in March 2019 due to phase 3 trial of lead monotherapy candidate not achieving primary endpoint, the company took some drastic steps including laying off 220 employees out of the 296. The company has curtailed most of its research & development activities except for the focused development of mirvetuximab based on guidelines from the U.S. FDA. A new phase 3 trial will be initiated before the year end, with a target of completion by 1Q-2022. Meanwhile, Immunogen plans to outsource its patented technologies and platforms. But I've been wrong many times. Hopefully it makes another run to 13. Best Regards, A51

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next